Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients.
Adult
Albuminuria
/ etiology
Creatinine
/ urine
Diet, Mediterranean
Energy Metabolism
/ physiology
Exercise
/ physiology
Female
Glomerular Filtration Rate
Humans
Insulin Resistance
/ physiology
Kidney
/ metabolism
Kidney Function Tests
Life Style
Liver
/ metabolism
Male
Metabolic Syndrome
/ complications
Middle Aged
Non-alcoholic Fatty Liver Disease
/ complications
Risk Factors
albumin-to-creatinine ratio
caloric restriction
glomerular hyperfiltration
increased energy expenditure
non-alcoholic fatty liver disease
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
15 Feb 2021
15 Feb 2021
Historique:
received:
15
01
2021
revised:
06
02
2021
accepted:
10
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
14
5
2021
Statut:
epublish
Résumé
To assess the efficacy of three lifestyle interventions on the reduction of liver fat content and metabolic syndrome (MetS), and whether such reductions would influence renal outcomes, we conducted a randomized controlled trial on 128 participants with MetS and non-alcoholic fatty liver disease (NAFLD), as well as available data on estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatine ratio (UACR). Patients were randomized in 1:1:1 ratio to either Conventional Diet, Mediterranean diet (MD)-high meal frequency, and MD-physical activity groups. Each intervention aimed at reducing caloric intake by 25%-30% of baseline intake and increase energy expenditure by 400 kcal/70 kg. Patients attended regular visits and were followed-up for 6 months. Increased albuminuria was present in 13.3% of patients, while 32.8% showed hyperfiltration. UACR reduction was associated with higher levels of UACR at baseline but not with changes in liver fat. eGFR decreased in patients presenting hyperfiltration at baseline and was associated with reduction in liver fat and insulin resistance, as well as with increase in energy expenditure (R
Identifiants
pubmed: 33672073
pii: nu13020629
doi: 10.3390/nu13020629
pmc: PMC7919687
pii:
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : Projects PI14/00636 and PI17/01827, and CIBEROBN CB12/03/30038, and Proyecto Intramural CIBER OBN18PI03
Organisme : Fundacio La Marató TV3
ID : 201630.10
Organisme : Health Department of the Government of Navarra
ID : 61/2015
Organisme : European Regional Development Fund
ID : N/A
Organisme : Balearic Islands Government
ID : 35/2011 and 23/2012
Organisme : COST
ID : CA16112
Organisme : IDISBA
ID : FOLIUM, PRIMUS, SYNERGIA, and LIBERI
Organisme : Spanish Ministry of Education
ID : Catalina M. Mascaró received an FPU PhD Grant
Références
J Family Med Prim Care. 2019 Mar;8(3):923-928
pubmed: 31041226
J Am Geriatr Soc. 1985 Apr;33(4):278-85
pubmed: 3989190
Endocrinol Nutr. 2012 Aug-Sep;59(7):429-37
pubmed: 22795577
J Clin Diagn Res. 2013 Aug;7(8):1764-6
pubmed: 24086908
Nephrol Dial Transplant. 2012 May;27(5):1708-14
pubmed: 22431709
Am J Epidemiol. 1994 Jun 15;139(12):1197-209
pubmed: 8209878
Diabetes Care. 2007 May;30(5):1212-8
pubmed: 17277038
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
J Lipid Res. 2017 Jun;58(6):1132-1142
pubmed: 28404638
J Hepatol. 2020 Apr;72(4):785-801
pubmed: 32059982
BMC Nephrol. 2013 Dec 05;14:271
pubmed: 24304464
Am J Physiol Renal Physiol. 2000 May;278(5):F817-22
pubmed: 10807594
Nutrition. 1989 Sep-Oct;5(5):303-11; discussion 312-3
pubmed: 2520314
Aliment Pharmacol Ther. 2017 Jan;45(2):332-344
pubmed: 27862096
J Pediatr. 2020 Jul;222:127-133
pubmed: 32381466
Clin Chim Acta. 2020 Dec;511:243-247
pubmed: 33148528
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Clin J Am Soc Nephrol. 2007 May;2(3):581-90
pubmed: 17699466
Diabetes Care. 2012 Oct;35(10):2061-8
pubmed: 22773704
Sci Rep. 2020 Jan 16;10(1):481
pubmed: 31949229
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
N Engl J Med. 2013 Apr 4;368(14):1279-90
pubmed: 23432189
Nat Rev Nephrol. 2017 May;13(5):297-310
pubmed: 28218263
Br J Nutr. 2014 Feb;111(4):643-52
pubmed: 23968597
Kidney Int. 2006 Oct;70(7):1214-22
pubmed: 16871239
J Nutr. 2011 Jun;141(6):1140-5
pubmed: 21508208
Nutr Hosp. 2011 Jan-Feb;26(1):16-26
pubmed: 21519726
J Ren Nutr. 2015 Jan;25(1):1-5
pubmed: 25091135
N Engl J Med. 2018 Jun 21;378(25):e34
pubmed: 29897866
Med Sci Sports Exerc. 2000 Aug;32(8):1431-7
pubmed: 10949009
Nephrol Dial Transplant. 2005 Oct;20(10):2024-8
pubmed: 16030047
Clin J Am Soc Nephrol. 2010 Jun;5(6):1003-9
pubmed: 20299365
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Metabolism. 2013 Mar;62(3):352-60
pubmed: 22999011
Am J Epidemiol. 1985 Jul;122(1):51-65
pubmed: 4014201
Radiology. 2013 May;267(2):422-31
pubmed: 23382291
Diabetes. 2017 Jan;66(1):75-86
pubmed: 27634224
BMC Nephrol. 2016 Nov 10;17(1):172
pubmed: 27832768
PLoS Med. 2014 Jul 22;11(7):e1001680
pubmed: 25050550
Am J Kidney Dis. 2003 Sep;42(3):466-73
pubmed: 12955674
Hypertension. 2005 Feb;45(2):198-202
pubmed: 15655123
Kidney Int. 2007 Apr;71(8):816-21
pubmed: 17332732
Eur J Gastroenterol Hepatol. 2018 Sep;30(9):986-994
pubmed: 29787418
Metabolism. 2010 Sep;59(9):1327-30
pubmed: 20096896
Diabetes Obes Metab. 2019 Nov;21(11):2368-2383
pubmed: 31297976
Clin J Am Soc Nephrol. 2012 Nov;7(11):1801-10
pubmed: 22917703
World J Diabetes. 2012 Jan 15;3(1):1-6
pubmed: 22253940
Fed Pract. 2019 Feb;36(2):64-71
pubmed: 30867626
Int J Obes (Lond). 2020 May;44(5):1129-1140
pubmed: 31641213
Nephrol Dial Transplant. 2013 Jan;28(1):29-36
pubmed: 23048172
Am J Kidney Dis. 2004 Feb;43(2):396; author reply 396-7
pubmed: 14750109
J Lipid Res. 2016 Dec;57(12):2099-2114
pubmed: 27330055
J Clin Endocrinol Metab. 2010 Jul;95(7):3347-51
pubmed: 20484475
Lancet Diabetes Endocrinol. 2014 May;2(5):417-26
pubmed: 24795255
J Am Soc Nephrol. 2017 Apr;28(4):1023-1039
pubmed: 28143897